文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

2019冠状病毒病疫苗接种对住院率和死亡率的影响:大流行早期临床结局的比较分析

Impact of COVID-19 Vaccination on Hospitalization and Mortality: A Comparative Analysis of Clinical Outcomes During the Early Phase of the Pandemic.

作者信息

Garduño-Orbe Brenda, Palma-Ramírez Paola Selene, López-Ortiz Eduardo, García-Morales Gabriela, Sánchez-Rebolledo Juan Manuel, Emigdio-Loeza Alexis, Gómez-García Anel, López-Ortiz Geovani

机构信息

Unidad de Medicina Familiar Número 26, Instituto Mexicano del Seguro Social, Acapulco 39700, Guerrero, Mexico.

Unidad de Medicina Familiar No. 29 con UMAA, Instituto Mexicano del Seguro Social, Acapulco 39906, Guerrero, Mexico.

出版信息

Infect Dis Rep. 2025 Jun 27;17(4):74. doi: 10.3390/idr17040074.


DOI:10.3390/idr17040074
PMID:40700321
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12286140/
Abstract

: Although COVID-19 vaccination has been effective in reducing severe illness and mortality, its differential clinical behavior in vaccinated and unvaccinated individuals during the early stages of the pandemic-especially in settings with partial coverage and real-world conditions-remains insufficiently characterized. : To assess differences in clinical presentation, comorbidity prevalence, hospitalization, and mortality between vaccinated and unvaccinated patients diagnosed with SARS-CoV-2 during the early phase of the pandemic. : An analytical cross-sectional study was conducted using 4625 electronic medical records of patients diagnosed with COVID-19 in Guerrero, Mexico, between 1 January and 31 December 2021. Variables included vaccination status, age, sex, comorbidities, symptom severity, clinical outcomes, and mortality. Statistical analyses involved chi-square tests, logistic regression for hospitalization probability, and Cox proportional hazards models for mortality risk. : Of the patients analyzed, 31.45% had received at least one vaccine dose. Fever, headache, cough, and anosmia were more frequent among vaccinated individuals ( < 0.001). Prostration and chest pain were strongly associated with hospitalization in both groups. In unvaccinated patients, smoking (OR = 4.75), obesity (OR = 3.85), and hypertension (OR = 2.94) increased hospitalization risk. Among vaccinated patients, diabetes mellitus (OR = 3.62) and hypertension (OR = 2.88) were key predictors. Vaccination was significantly associated with lower odds of hospitalization (OR = 0.38; 95% CI: 0.26-0.55) and reduced mortality risk (HR = 0.24; 95% CI: 0.08-0.71). : Vaccination status was a significant protective factor for both hospitalization and mortality; however, clinical symptoms and comorbidity-related risks varied, highlighting the need for individualized patient management strategies.

摘要

虽然新冠病毒疫苗接种在降低重症和死亡率方面已见成效,但其在疫情早期接种和未接种人群中的临床差异表现——尤其是在部分接种覆盖和现实条件下——仍未得到充分描述。 为评估在疫情早期被诊断为感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的接种和未接种患者之间的临床表现、合并症患病率、住院率和死亡率差异。 采用分析性横断面研究,使用了2021年1月1日至12月31日期间墨西哥格雷罗州4625例被诊断为新冠病毒病(COVID-19)患者的电子病历。变量包括疫苗接种状况、年龄、性别、合并症、症状严重程度、临床结局和死亡率。统计分析包括卡方检验、住院概率的逻辑回归以及死亡风险的Cox比例风险模型。 在分析的患者中,31.45%至少接种过一剂疫苗。接种者中发热、头痛、咳嗽和嗅觉丧失更为常见(<0.001)。两组中乏力和胸痛与住院密切相关。在未接种患者中,吸烟(比值比[OR]=4.75)、肥胖(OR=3.85)和高血压(OR=2.94)增加住院风险。在接种患者中,糖尿病(OR=3.62)和高血压(OR=2.88)是关键预测因素。接种疫苗与较低的住院几率(OR=0.38;95%置信区间[CI]:0.26 - 0.55)和降低的死亡风险(风险比[HR]=0.24;95%CI:0.08 - 0.71)显著相关。 疫苗接种状况是住院和死亡的重要保护因素;然而,临床症状和合并症相关风险存在差异,凸显了个性化患者管理策略的必要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3021/12286140/dfee99a99a07/idr-17-00074-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3021/12286140/e69ec01441ea/idr-17-00074-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3021/12286140/11d42f39f00a/idr-17-00074-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3021/12286140/62aacb391132/idr-17-00074-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3021/12286140/dfee99a99a07/idr-17-00074-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3021/12286140/e69ec01441ea/idr-17-00074-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3021/12286140/11d42f39f00a/idr-17-00074-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3021/12286140/62aacb391132/idr-17-00074-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3021/12286140/dfee99a99a07/idr-17-00074-g004.jpg

相似文献

[1]
Impact of COVID-19 Vaccination on Hospitalization and Mortality: A Comparative Analysis of Clinical Outcomes During the Early Phase of the Pandemic.

Infect Dis Rep. 2025-6-27

[2]
RECOVID: Retrospective Observational Study of Renal Outcomes and Long-Term Mortality in Patients With COVID-19-Associated AKI, A Comparison Between Vaccinated and Unvaccinated Patients.

Kidney Med. 2025-6-18

[3]
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.

Cochrane Database Syst Rev. 2022-5-20

[4]
Impact of Preexisting Rare Diseases on COVID-19 Severity, Reinfection, and Long COVID, and the Modifying Effects of Vaccination and Antiviral Therapy: A Retrospective Study from the N3C Data Enclave.

medRxiv. 2025-7-10

[5]
Safety of SARS-CoV-2 vaccination during pregnancy- obstetric outcomes from a large cohort study.

BMC Pregnancy Childbirth. 2022-2-28

[6]
Antibody tests for identification of current and past infection with SARS-CoV-2.

Cochrane Database Syst Rev. 2022-11-17

[7]
Risk of thromboembolism in patients with COVID-19 who are using hormonal contraception.

Cochrane Database Syst Rev. 2023-1-9

[8]
COVID-19 Hospitalization and Mortality Trends Among US Dialysis Patients by Race/Ethnicity and Vaccination Status.

Kidney Med. 2025-5-16

[9]
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.

Cochrane Database Syst Rev. 2022-9-20

[10]
A retrospective cohort study on early antibiotic use in vaccinated and unvaccinated COVID-19 patients.

J Med Virol. 2024-3

本文引用的文献

[1]
Socioeconomic and temporal heterogeneity in SARS-CoV-2 exposure and disease in England from May 2020 to February 2023.

Sci Adv. 2025-5-23

[2]
Interim Estimates of 2024-2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years - VISION and IVY Networks, September 2024-January 2025.

MMWR Morb Mortal Wkly Rep. 2025-2-27

[3]
Evaluating the Effectiveness of mRNA-1273.815 Against COVID-19 Hospitalization Among Adults Aged ≥ 18 Years in the United States.

Infect Dis Ther. 2025-1

[4]
How well do different COVID-19 vaccines protect against different viral variants? A systematic review and meta-analysis.

Trans R Soc Trop Med Hyg. 2025-1-3

[5]
Using causal diagrams within the Grading of Recommendations, Assessment, Development and Evaluation framework to evaluate confounding adjustment in observational studies.

J Clin Epidemiol. 2024-11

[6]
Methodological Tutorial Series for Epidemiological Studies: Confounder Selection and Sensitivity Analyses to Unmeasured Confounding From Epidemiological and Statistical Perspectives.

J Epidemiol. 2025-1-5

[7]
The impact of comorbidity status in COVID-19 vaccines effectiveness before and after SARS-CoV-2 omicron variant in northeastern Mexico: a retrospective multi-hospital study.

Front Public Health. 2024

[8]
Real-world Effectiveness of mRNA COVID-19 Vaccines Among US Nursing Home Residents Aged ≥65 Years in the Pre-Delta and High Delta Periods.

Open Forum Infect Dis. 2024-1-29

[9]
The evolving landscape of SARS-CoV-2 vaccination in Mexico: real-world evidence in Mexican pensioners.

Lancet Reg Health Am. 2023-10-31

[10]
COVID-19 vaccine effectiveness and evolving variants: understanding the immunological footprint.

Lancet Respir Med. 2023-5

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索